

RESPONSE TO OFFICE ACTION

A. Status of the Claims

Claims 1, 8 and 14 have been amended to correct typographical errors, however these amendments in way limit the scope of the claims. No claims have been canceled herein. New Claims 18-65 have been added and break-out the chemical groups in Claims 1 and 14. Thus Claims 1-6, 8, 14-16, and 18-65 are currently active.

Support for the new Claims 18-41 can be found in Claim 1 as originally filed and throughout the specification. Likewise support for new Claims 42-65 can be found in the original Claim 14, as well as in the specification.


B. Rejection of Claims Under 35 U.S.C. §112, Second Paragraph

The action rejects Claim 8 as failing to comply with the written description requirement stipulated in 35 U.S.C. §112. Applicant respectfully traverses, as Claim 8 clearly meets the requires set forth by 35 U.S.C. §112. Written description for tumor cells comprising a glioma, a fibrosarcoma, a retinoblastoma, and a melanoma can be found in the specification on page 13 line 3. Applicant also points out that there is written description for each of the above mentioned tumor types in the original Claim 8, as it was initially filed on October 28, 2003. For the reasons stipulated herein the examiner is respectfully asked to withdraw the rejection of Claim 8.

D. Conclusion

This is submitted to be a complete response to the referenced Office Action. In conclusion, Applicant submits that, in light of the foregoing remarks, the present case is in condition for allowance and such favorable action is respectfully requested.

The Examiner is invited to contact the undersigned at (512) 536-3055 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,


David L. Parker
Reg. No. 32,165
Attorney for Applicants

FULBRIGHT & JAWORSKI, L.L.P.
600 Congress Ave., Ste. 1900
Austin, Texas 78701
(512) 536-3055
(512) 536-4598 (facsimile)

Date: March 3, 2005